Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Paradigm Communications

Access and elimination: the future of DAAs in hepatitis C

Published in Pharmaphorum January 2017

Research Partnership

- PMLiVE

Two new hepatitis C therapies fast-tracked in Europe

EMA speeds review process for Gilead and AbbVie treatments

- PMLiVE

Gilead files hepatitis C salvage regimen in US

Seeks FDA approval for combination of Epclusa and voxilaprevir

- PMLiVE

Could Gilead face early Sovaldi generics in Europe?

EU patent protection for the hepatitis C virus drug will end in 2024

- PMLiVE

Merck & Co gets EU green light for hep C drug Zepatier

Will enter a market currently dominated by Gilead's Harvoni and Sovaldi

- PMLiVE

Gilead launches European hep C awareness drive

Aims to highlight significance of cure through patient storytelling initiative

Gilead Sciences

Gilead’s hepatitis C sales start to slide – the question is how quickly?

CEO anticipates eventual “equilibrium” through shift toward treatment of less severely ill patients

- PMLiVE

Gilead’s universal hep C therapy Epclusa approved in EU

European nod for first pan-genotypic treatment follows recent FDA licensing

- PMLiVE

FDA approves Gilead’s ‘universal’ hep C combination Epclusa

Adds a third Sovaldi-based treatment to the firm’s portfolio

Gilead Sciences

Gilead, Merck get CHMP backing for new hep C combinations

Approval of Epclusa and Zepatier will see the pan-genotypic drugs compete for market share

- PMLiVE

AbbVie hepatitis C combo shows high cure rates

Presents promising new phase II data across all six major HCV genotypes

- PMLiVE

Harvoni cleared for broader use in hepatitis C

Gilead Sciences’ drug wins US approval for use in liver transplant patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links